CCCC

C4 Therapeutics, Inc. (CCCC) - 10-K Summary

Business Context and Reporting Period

Company: C4 Therapeutics, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: C4 is a clinical-stage biopharmaceutical company developing targeted protein degradation (TPD) therapies using its proprietary TORPEDO platform. The company focuses on oncology, inflammation, neuroinflammation, and neurodegeneration. It has no approved products and generates revenue solely through collaboration and license agreements.

Key Financial Metrics

Note: The company reported an impairment loss on right-of-use assets of $10.7 million in 2025 due to a new sublease agreement.

Material Changes vs. Prior Period

• Revenue: Increased slightly by $0.4 million (1.0%) to $35.9 million. This was driven by a $11.2 million increase from the Merck KGaA collaboration and a $4.8 million increase from Roche, partially offset by a $14.9 million decrease from Biogen as its research term concluded.
• Operating Expenses: Total operating expenses decreased by $4.0 million to $151.2 million. R&D expenses declined by $6.4 million due to lower preclinical costs and stock-based compensation. G&A expenses decreased by $5.9 million, primarily due to reduced stock-based compensation.
• Liquidity: Cash and marketable securities increased to $297.1 million, bolstered by a $116.9 million net proceeds from an underwritten equity offering in October 2025 and $9.4 million from at-the-market offerings.
• Capital Structure: In October 2025, the company issued 21.9 million shares, 28.7 million pre-funded warrants, and 101.2 million Class A/B warrants. The company also increased authorized common stock from 150 million to 300 million shares.

Guidance, Outlook, and Risks

• Clinical Progress:
  • Cemsidomide (Multiple Myeloma): Phase 2 MOMENTUM trial enrollment began in February 2026. A Phase 1b trial in combination with elranatamab (supplied by Pfizer) is ongoing.
  • CFT8919 (NSCLC): Partner Betta Pharma is conducting a Phase 1 trial in Greater China; data will inform ex-China strategy.
• Collaborations: Active agreements with Merck KGaA, Roche, Betta Pharma, and Biogen. The Merck (MSD) agreement was terminated in late 2025, with remaining revenue recognized. A new supply agreement with Pfizer was signed in September 2025.
• Outlook: Management believes current cash resources ($297.1 million) are sufficient to fund operations through the end of 2028. The company expects to continue incurring significant losses as it advances clinical trials.
• Risks:
  • Dependence on third-party manufacturers and collaborators.
  • Uncertainty of clinical trial outcomes and regulatory approval.
  • Need for substantial additional capital to complete development and commercialization.
  • Impact of potential changes in healthcare legislation and drug pricing (e.g., Inflation Reduction Act, MFN pricing proposals).

Investor Verification Checklist

• Cash Runway: Verify the $297.1 million cash balance and the assumption that it funds operations through 2028, considering the high burn rate (~$105M annual net loss).
• Warrant Dilution: Assess the potential dilution from 101.2 million outstanding warrants (Class A/B) and 28.7 million pre-funded warrants issued in the 2025 offering.
• Revenue Sustainability: Confirm the timeline for future milestone payments from partners (Merck KGaA, Roche, Biogen) given the conclusion of the Biogen research term and the termination of the Merck (MSD) deal.
• Clinical Milestones: Monitor enrollment and data readouts for the cemsidomide Phase 2 MOMENTUM trial and the CFT8919 Phase 1 trial in China.
• Impairment Charges: Review the $10.7 million impairment charge related to the Watertown facility sublease and its impact on future operating costs.